Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Karagiannis, Asterios [Clear All Filters]
Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs..
Curr Vasc Pharmacol. 14(2), 208-10.
(2016). The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data..
Hormones (Athens). 17(1), 83-95.
(2018). The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis..
Curr Vasc Pharmacol. 8(6), 792-803.
(2010). Effect of antihypertensive drug-associated diabetes on cardiovascular risk..
Hellenic J Cardiol. 51(3), 195-9.
(2010). The effect of continuous positive airway pressure therapy on blood pressure and arterial stiffness in hypertensive patients with obstructive sleep apnea..
Sleep Breath. 18(3), 635-40.
(2014). Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension..
Curr Vasc Pharmacol. 16(4), 393-400.
(2018). The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture..
Thromb Haemost. 110(2), 257-63.
(2013). Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study..
Curr Med Res Opin. 22(5), 873-83.
(2006). Effect of Nebivolol and Olmesartan on 24-Hour Brachial and Aortic Blood Pressure in the Acute Stage of Ischemic Stroke..
Int J Hypertens. 2019, 9830295.
(2019). Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes..
Acta Diabetol. 45(1), 23-30.
(2008). The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins..
Curr Pharm Des. 23(10), 1477-1483.
(2017). Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report..
Curr Vasc Pharmacol. 12(3), 505-11.
(2014). The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus.
Journal of Hypertension. 1.
(2019). The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials..
J Hypertens. 37(7), 1334-1343.
(2019). The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Future Medicinal Chemistry. 2019 Jun;11(11):1285-1303.
(2019). The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection..
Future Med Chem. 11(11), 1285-1303.
(2019). The effect of SGLT2 inhibitors on cardiovascular events and renal function..
Expert Rev Clin Pharmacol. 10(11), 1251-1261.
(2017). Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study..
Nephrol Dial Transplant. 22(1), 118-27.
(2007). Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy..
Curr Vasc Pharmacol.
(2014). Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review..
Curr Med Res Opin. 29(10), 1263-74.
(2013). The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes..
Lancet Diabetes Endocrinol. 2(5), 362-3.
(2014). Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients..
Am J Cardiol. 101(4), 483-5.
(2008). Effects of lipid lowering drugs on arterial stiffness. One more way to reduce cardiovascular risk?.
Curr Vasc Pharmacol.
(2019). Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure..
Curr Pharm Des. 20(40), 6306-13.
(2014). Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness..
J Am Soc Hypertens. 8(2), 74-82.
(2014).